US 10,646,600 B2Granted

HER2 polypeptides useful for imaging and monitoring tumors and cancers

AssigneesImperial Innovations Limited, Ge Healthcare Limited

InventorsDuncan Robert R. Hiscock, Eric Aboagye, Peter Iveson, Quang-De Nguyen, Susan Hoppmann, Sebastian Trousil, Maciej Kaliszczak, Giampaolo Tomasi

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.

Claims5

Dependent claims

A method of monitoring a dose dependent response HSP90 inhibition, the method comprising:

(a) administering [18F]GE-226 (SEQ ID NO 1) to a HER2 bearing subject followed by conducting positron emission tomography (PET) scan of the subject to determine an amount of uptake of [18F]GE-226 in the subject,
(b) administering a first amount of a HSP90 inhibitor to the subject and waiting for at least 24 hours before administering [18F]GE-226 to the subject followed by conducting a second PET scan of the subject to determine the amount of uptake of [18F]GE-226,
(c) repeat step (b) with at least one additional amount of the HSP90 inhibitor, and
(d) comparing the PET scan results from (a)-(c) to monitor the dose dependent response of the subject to HSP90 inhibition.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 14/900,841Filed 24 Jun 2014 · us provisional application
Priority: 27 Jun 2013
Published: US 2016/0144062 A126 May 2016
Granted: 12 May 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 51/1051
Against animal or human tumor cells or tumor cell determinants: the tumor cell being from breast, e.g. the antibody being herceptin
A61K 51/1063
Against animal or human tumor cells or tumor cell determinants: the tumor cell being from stomach or intestines
A61K 51/1072
Against animal or human tumor cells or tumor cell determinants: the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or…
A61P 35/00
Antineoplastic agents